Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study

Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study

Abstract Background Rilpivirine is safe and effective in HIV-naïve patients with low baseline HIV-RNA or in switch strategy. It offers the advantages of few drug-drug interactions and a favourable toxicity profile. We aimed to determine the reasons for prescribing the rilpivirine (RPV)/tenofovir dis...

Full description

Bibliographic Details
Main Authors: Delphine Sculier, Angèle Gayet-Ageron, Manuel Battegay, Matthias Cavassini, Jan Fehr, Cedric Hirzel, Patrick Schmid, Enos Bernasconi, Alexandra Calmy, for the Swiss HIV Cohort Study
Format: Article
Language:English
Published: BMC 2017-07-01
Series:BMC Infectious Diseases
Subjects:
HIV-1
Rilpivirine
First-line regimen
Treatment simplification
Virological response
Safety
Online Access:http://link.springer.com/article/10.1186/s12879-017-2579-2

Internet

http://link.springer.com/article/10.1186/s12879-017-2579-2

Similar Items